Z

Zenas Biopharma Inc
NASDAQ:ZBIO

Watchlist Manager
Zenas Biopharma Inc
NASDAQ:ZBIO
Watchlist
Price: 19.63 USD -3.77% Market Closed
Market Cap: $1.1B

Operating Margin

-1 304.6%
Current
Declining
by 391.9%
vs 3-y average of -912.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 304.6%
=
Operating Income
$-195.7m
/
Revenue
$15m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 304.6%
=
Operating Income
$-195.7m
/
Revenue
$15m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Zenas Biopharma Inc
NASDAQ:ZBIO
1.1B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 94% of companies in the United States of America
Percentile
6th
Based on 14 112 companies
6th percentile
-1 304.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Zenas Biopharma Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.

ZBIO Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 304.6%
=
Operating Income
$-195.7m
/
Revenue
$15m
What is Zenas Biopharma Inc's current Operating Margin?

The current Operating Margin for Zenas Biopharma Inc is -1 304.6%, which is below its 3-year median of -912.7%.

How has Operating Margin changed over time?

Over the last 2 years, Zenas Biopharma Inc’s Operating Margin has decreased from -42.7% to -1 304.6%. During this period, it reached a low of -3 277.8% on Dec 31, 2024 and a high of -42.7% on Aug 30, 2023.

Back to Top